This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): ABT-267, Viekira (ombitasvir + paritaprevir + ritonavir), VIEKIRAX (ombitasvir + paritaprevir + ritonavir) [EU, JP], Viekira Pak / Holkira Pak (co-packaged with dasabuvir tablets), Technivie (Viekira in combination with ribavirin)
Our Hepatitis C revenue model includes a forecast for the combination of ABT-333, ABT-450, and ABT-267.
Historical revenues for the Viekira Pak are recorded under Exviera.
ABT-267 is a novel NS5A inhibitor with inhibitory concentrations in the picomolar range against genotype 1a and 1b NS5A proteins in subgenomic replicon systems.
Enanta and Abbott (now AbbVie)
In December 2006, Enanta and Abbott announced a worldwide agreement to collaborate on the discovery, development and commercialization of HCV NS3 and NS3/4A protease inhibitors and HCV- protease-inhibitor-containing drug combinations. Under the agreement, Abbott is responsible for all development and commercialization activities for ABT-450. Enanta received $57 million in connection with signing the collaboration agreement, has received $55 million in subsequent clinical milestone payments, is entitled to receive $40 million in connection with regulatory filings, and is eligible to receive up to an additional $155 million in payments for regulatory and reimbursement approval milestones, as well as double-digit royalties worldwide on any revenue allocable to the collaborations protease inhibitors. Also, for any additional collaborative HCV protease inhibitor product candidate developed under the agreement, Enanta holds an option to modify the...See full deal structure in Biomedtracker
Partners: Enanta Pharmaceuticals, Inc.
Additional information available to subscribers only: